Oncoustics’ Post

I learned that "big-pharma" despite it's perceived notoriety, conducts massively important life-saving research and drug development, alongside the bioscience startup community. Brilliant #FTLive Funding Biopharma Innovation panel with Bicycle Therapeutics, Bristol Myers Squibb, Syneos Health, and Cure. How can VCs join together with companies to commercially accelerate women & diverse led biopharma startups? #OverlookedVisionaries #Startups #Biopharma

Even in early stage biotech there is power in numbers... When there was ample capital available it made sense for early stage biotech companies to stay largely closed off and forge the drug discovery valley of death on their own. There seemed to be endless capital to stay alive. VC was willing to take a lot of risky and even questionable bets. But regardless of that, the failure rate in biotech and particularly therapeutics has always been high. Tons of ideas getting funded with sky high valuations never changed that. So even as early stage capital returns to biotech, there is time to consider an inflection point. Early stage biotechs should think about more early stage collaboration or even combining of ideas. Sure, that means that you have doubled the number of founders and split the equity pie amongst more individuals. But this could be a way to de-risk. It could be a way to reach the clinic quicker or an exit quicker. I see a lot of good early stage ideas that could be made great if they spoke to other early stage ideas and considered joining forces. Sometimes 1 + 1 does equal 3. Power in numbers. Let's consider more collaboration between early stage biotechs. Consortium of early ventures? #Biotech #VentureCapital #Therapeutics #DrugDiscovery

We appreciate the support of NIH SEED. We look forward to participating at #LifeSciencesSummit. And are excited to present the developments at Epivario, including our advancement of novel treatments for substance use disorder. #epigenetics #neuroepigenetics #neuroscience #addictiontreatment #biotech #biotechnology #opioidusedisorder

#fundingalert 💼Company: CinRx Pharma 💰Funding: $73Million ⚡Round: New Round 👥Investors: Prior investors CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx’s approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx’s central infrastructure and operating team. CinRx plans to use the funds to advance development of its existing portfolio programs and assets to expand in key areas of high unmet medical need. Jonathan Isaacsohn, MD, FACC, Brian Murphy, MD, MPH, FIDSA, Mary Bond, Gavin Samuels, Sally Dressman Read more - https://lnkd.in/g4p_ZDfF To share your startup story write us on - contact@startuprise.io #CinRxPharma #biotechstartup #development #infrastructure #funding #fundingnews #news #startup #startupnews #startuprise

Global Digital Therapeutics (DTx) Startup Ecosystem: Deep Dive Analysis Through an extensive search and review of publicly available information, 172 startups were selected for detailed analysis based on specific criteria: Business Profile, Product, Technological Innovation including Patents, Investment and Fund Raising, Key Leadership, Revenue, Market, Clinical Trials, and Reimbursement Contents Global DTx Startup Landscape 1.5Q 2024 Global DTx Startups' Key Target Health Conditions 1.5Q 2024  Global DTx Product Landscape 1.5Q 2024  Global DTx Innovation (Patent) Landscape 1.5Q 2024 Partnerships between DTx Startups and Pharmaceuticals & Clinics 1.5Q 2024 Global DTx Startup Fund Raising Cases 1.5Q 2024 Conundrum in DTx Ecosystem Future of Global DTx Ecosystem Analysis Samples Expert invitation for comment: Koen Kas Tony J Simon, Ph.D. Kelly Stein-Marcus Marguerite Manteau-Rao, LCSW, MBA Janvi Parmar Ravi Janapureddy Howard Berman, PhD Seth Feuerstein Torsten Schröder, MD, PhD Logan Harper Stephen Hamm, MBA Bikram Gangwar Michaël Cardinal Sean G.(Sungjee) Kang, MD, MPH Robert A. Renata Redondo Bonaldi, PhD, Global MBA Ian Miller Jon Redmond Joshua Bull Klaudia Dobrev Marcelo Duhalde #digitaltherapeutics #dtx #startup #product #innovation #patent #fundraising #ecosystem 

🔬 Don't miss the Early-Stage Therapeutics panel at RESI Boston 2024! 💊 Join industry leaders as they discuss: • Decision-making processes for biotech investments • Hot areas in therapeutics • Standing out in crowded markets • Common pitfalls to avoid • Recent success stories Gain invaluable insights on sourcing novel assets, emerging technologies, and navigating the path to commercialization. Featured panelists: • Ashim Subedee - Division of Research Innovation and Ventures • Chris Garabedian - Xontogeny • Jill Goldstein - Vida Ventures, LLC • Squire Severance - Syridex Bio • Claire Leurent PhD MBA - AbbVie Ventures • Allan Gobbs - ATEM Capital Register now for RESI Boston (September 25-27) to connect with these experts and other early-stage investors: https://lnkd.in/e7QS-AZi Don't miss this opportunity to accelerate your biotech startup's growth! #RESIBoston #Biotech #Therapeutics #Investing #StartupGrowth #VentureCapital #Pharma #Innovation #EarlyStageInvesting #Networking

🎉 Congratulations to Xaira Therapeutics!🎉 Xaira Therapeutics, a #generative AI based drug discovery startup led by protein design giants such as David Baker was launched this week with a $1Bn investment! This is yet another testament to the growing confidence in AI's potential to revolutionize biotechnology. At Enzymit, we share similar vision and commitment. We harness groundbreaking AI technologies, including diffusion models and large language models (LLMs), which are crucial in our efforts to transform bioproduction. Our AI tools enable us to design novel enzymes with unprecedented precision. Our approach focuses on the dynamic and intricate nature of enzymes, which are essential catalysts in bioproduction processes. Novel enzymes are key in allowing us to synthesize valuable chemicals such as hyaluronic acid and human milk oligosaccharides (HMOs), making these valuable substances more affordable and accessible. It's an exhilarating time in the computational protein design space, and we are proud to be among the leaders propelling this innovation. Stay connected with Enzymit as we continue to push the boundaries of biotechnology! Hetu K Arvind Rajpal Institute for Protein Design, University of Washington

Exclusive: Former Pfizer chief commercial officer Angela Hwang will become Flagship Pioneering's next CEO-partner and chief executive of its startup Metaphore Biotechnologies, which seeks to mimic nature to create new medicines, including obesity management treatments with partner Novo Nordisk. “What I’m going to be able to bring are the lessons that I have learned launching so many products across so many different categories,” Hwang said in an interview with Endpoints News. “Now being able to bring all of this early and be able to shape these programs early, I think, is truly something that I can do to round out my career.” #flagshippioneering #pfizer #metaphore #biotechceo #biotech

Biotech execs and VC leaders recently spoke with Biopharma Dive about the current market cycle and its effects on both startups and big pharma companies. I especially appreciate the point Kevin Marks, CEO of Delphia Therapeutics, made about regularly reassessing R&D hypotheses. Sometimes information changes and we need to think critically about the best path forward. And that doesn’t always mean shutting down a program—Kevin shared an anecdote about successfully pivoting a program to a new indication where it’s now approved. AI and advanced analytics offer us more information than ever. One way we can take advantage of AI is to use it as a tool to regularly reexamine our R&D hypothesis throughout a program’s journey. #Pharma #Biopharma https://lnkd.in/dxs6WEEv  

Wow. Groundbreaking scientific discoveries are happening right here in California, and you must check out the latest advancements by CA-based biotech companies. These trailblazers are transforming the landscape of healthcare, life science and industries alike! 🧬 Introducting our article "Spotlight on California Biotech Startups: Pioneers in Revolutionary Innovations" that shares the compelling stories of these exciting startups. Let it inspire you. 👇 https://lnkd.in/d_TKXKhP ☀️ Spotlight on: 1. Resilience - Founded by Drew Oetting, and Rahul Singhvi 2. ACELYRIN, INC. - Founded by Robert Carey, and Shao-Lee Lin, MD, PhD 3. Onc.AI - Founded by Akshay Nanduri, and Salmaan Ahmed 4. Graphite Bio - Founded by Daniel Dever, Maria Grazia Roncarolo, Matthew Porteus 5. Revelation Biosciences Inc. - Founded by Chester S. Zygmont, III 6. Perceive Biotherapeutics, Inc. 7. Longboard Pharmaceuticals - Founded by Kevin R. Lind 8. Shoreline Biosciences, Inc. - Founded by Dan S. Kaufman, Kleanthis G. Xanthopoulos, Marios Fotiadis, Steven Holtzman 9. Cellanome - Founded by Mostafa Ronaghi 10. Pardes Biosciences - Founded by Uri Lopatin, MD 11. Sonoma Biotherapeutics - Founded by Alexander Rudensky, Fred Ramsdell, Jeffrey Bluestone, Qizhi Tang Get to know their amazing work, their innovative solutions, and how they are gearing up to own the future. #biotech #startups #innovation #California #healthcare #lifesciences #revolutionary #pioneers